111 related articles for article (PubMed ID: 34918690)
1. Association of serum fibroblast growth factor 21 with kidney function in a population-based Chinese cohort.
Zhang R; Li Y; Zhou X; Zhang F; Li M; Zhang S; Zhang X; Wen X; Ji L
Medicine (Baltimore); 2021 Dec; 100(50):e28238. PubMed ID: 34918690
[TBL] [Abstract][Full Text] [Related]
2. Relationship of fibroblast growth factor 21 with kidney function and albuminuria: multi-ethnic study of atherosclerosis.
Anuwatmatee S; Allison MA; Shlipak MG; McClelland RL; Kramer H; Tang S; Hou L; Rye KA; Ong KL
Nephrol Dial Transplant; 2019 Jun; 34(6):1009-1016. PubMed ID: 29771383
[TBL] [Abstract][Full Text] [Related]
3. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria.
Lee CH; Hui EY; Woo YC; Yeung CY; Chow WS; Yuen MM; Fong CH; Xu A; Lam KS
J Clin Endocrinol Metab; 2015 Apr; 100(4):1368-75. PubMed ID: 25625802
[TBL] [Abstract][Full Text] [Related]
4. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese.
Lin Z; Zhou Z; Liu Y; Gong Q; Yan X; Xiao J; Wang X; Lin S; Feng W; Li X
PLoS One; 2011 Apr; 6(4):e18398. PubMed ID: 21525989
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease.
Gómez-Sámano MÁ; Vargas-Abonce VP; Martínez-Sánchez FD; Palacios-Báez L; Vera-Zertuche JM; Navarro-Flores MF; Morales-García MG; Fonseca-Correa JI; Zuarth-Vázquez JM; Vega-Vega O; Correa-Rotter R; Rincón-Pedrero R; Morales-Buenrostro LE; Alberú-Gómez J; Ramírez-González JB; Pacheco-Domínguez RL; López-Cervantes M; Mendoza-de-la-Garza MLÁ; Baeza-Arias YV; Espinosa-Cuevas Á; López-Carrasco G; López-Estrada A; Guillén-Pineda LE; Gómez-Pérez FJ; Cuevas-Ramos D
Ther Adv Endocrinol Metab; 2021; 12():20420188211001160. PubMed ID: 33854753
[TBL] [Abstract][Full Text] [Related]
6. Serum uric acid to creatinine ratio: A predictor of incident chronic kidney disease in type 2 diabetes mellitus patients with preserved kidney function.
Gu L; Huang L; Wu H; Lou Q; Bian R
Diab Vasc Dis Res; 2017 May; 14(3):221-225. PubMed ID: 28183204
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of the adipokine FGF21 depend on renal function.
Stein S; Bachmann A; Lössner U; Kratzsch J; Blüher M; Stumvoll M; Fasshauer M
Diabetes Care; 2009 Jan; 32(1):126-8. PubMed ID: 18840768
[TBL] [Abstract][Full Text] [Related]
8. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease.
Shen Y; Ma X; Zhou J; Pan X; Hao Y; Zhou M; Lu Z; Gao M; Bao Y; Jia W
Cardiovasc Diabetol; 2013 Aug; 12():124. PubMed ID: 23981342
[TBL] [Abstract][Full Text] [Related]
9. Genetic and environmental influences on the associations between change in kidney function and changes in cardiometabolic factors in Koreans.
Song YM; Sung J; Lee K
Clin Exp Nephrol; 2017 Jun; 21(3):474-480. PubMed ID: 27339447
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events.
Wu L; Qian L; Zhang L; Zhang J; Zhou J; Li Y; Hou X; Fang Q; Li H; Jia W
J Am Heart Assoc; 2020 Jun; 9(11):e015226. PubMed ID: 32431189
[TBL] [Abstract][Full Text] [Related]
11. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels.
Cuevas-Ramos D; Almeda-Valdes P; Gómez-Pérez FJ; Meza-Arana CE; Cruz-Bautista I; Arellano-Campos O; Navarrete-López M; Aguilar-Salinas CA
Eur J Endocrinol; 2010 Sep; 163(3):469-77. PubMed ID: 20566587
[TBL] [Abstract][Full Text] [Related]
12. Elevated Serum Uric Acid Level Predicts Rapid Decline in Kidney Function.
Kuwabara M; Bjornstad P; Hisatome I; Niwa K; Roncal-Jimenez CA; Andres-Hernando A; Jensen T; Milagres T; Sato Y; Garcia G; Ohno M; Lanaspa MA; Johnson RJ
Am J Nephrol; 2017; 45(4):330-337. PubMed ID: 28285309
[TBL] [Abstract][Full Text] [Related]
13. Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus.
Lee CH; Woo YC; Chow WS; Cheung CYY; Fong CHY; Yuen MMA; Xu A; Tse HF; Lam KSL
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588089
[TBL] [Abstract][Full Text] [Related]
14. Body mass index is an independent predictive factor for kidney function evaluated by glomerular filtration rate in a community-dwelling population.
Duan Y; Wang X; Zhang J; Ye P; Cao R; Yang X; Bai Y; Wu H
Eat Weight Disord; 2019 Aug; 24(4):731-738. PubMed ID: 28871501
[TBL] [Abstract][Full Text] [Related]
15. White blood cell count predicts the odds of kidney function decline in a Chinese community-based population.
Fan F; Jia J; Li J; Huo Y; Zhang Y
BMC Nephrol; 2017 Jun; 18(1):190. PubMed ID: 28592280
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 21 (FGF21) in children and adolescents with chronic kidney disease.
Gamrot Z; Adamczyk P; Świętochowska E; Roszkowska-Bjanid D; Gamrot J; Szczepańska M
Physiol Res; 2020 Jul; 69(3):451-460. PubMed ID: 32469231
[TBL] [Abstract][Full Text] [Related]
17. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL; Januszewski AS; O'Connell R; Buizen L; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Rye KA; Keech AC;
Diabetologia; 2015 Sep; 58(9):2035-44. PubMed ID: 26055067
[TBL] [Abstract][Full Text] [Related]
18. Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m
Zhou F; Yu G; Wang G; Liu Y; Zhang L; Wang W; Chen N
Clin Exp Nephrol; 2019 Jul; 23(7):871-879. PubMed ID: 30734168
[TBL] [Abstract][Full Text] [Related]
19. Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study.
Choi JR; Kim JY; Park IH; Huh JH; Kim KW; Cha SK; Park KS; Sohn JH; Park JT; Koh SB
Yonsei Med J; 2018 Mar; 59(2):287-293. PubMed ID: 29436198
[TBL] [Abstract][Full Text] [Related]
20. Genetic Variants Flanking the
Yu W; Zhu H; Chen X; Gu X; Zhang X; Shen F; Jia W; Hu C
J Diabetes Res; 2019; 2019():9387358. PubMed ID: 31205953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
